Company Overview - Humana is the second-largest Medicare Advantage firm with an 18% market share and 5.5 million enrolled members, holding the largest market share in nine states, including Florida at 31% [1] - Elevance Health has the highest Medicare Advantage market share in Ohio at 25%, with a total Medicare membership of 2.91 million [6] - UnitedHealth Group leads the Medicare Advantage market with a 29% share and 8.9 million enrolled members, nearly equal to the combined total of the second and third-largest players [14] Financial Performance - Humana reported Q1 2024 revenue from Medicare Advantage premiums of $24.44 billion, a 13.3% increase from $21.57 billion a year earlier, accounting for 82% of its total revenue [2] - Elevance Health's overall revenue for Q1 2024 was $42.58 billion, a 1.0% increase year-over-year, with an operating income of $2.94 billion, up 12.2% from Q1 2023 [6][7] - UnitedHealth's Medicaid & Retirement segment generated $35.49 billion in Q1 2024, an 8% increase, contributing 47.1% to the company's overall revenue [15] Earnings Projections - Humana expects adjusted earnings per share (EPS) of $16.00 for 2024, down from $26.09 in 2023 due to higher Medicare Advantage medical costs [3] - Elevance Health anticipates adjusted EPS of $37.20 or higher for 2024 [7] Market Valuation - Humana's shares are trading at 22.3 times the 2024 earnings estimate, slightly above its five-year average of 18.3 times [4] - Elevance Health trades at 14.3 times its projected earnings, also slightly above its five-year average [7] Industry Context - The privatization of Medicare has led to significant growth for private insurers, with approximately 50% of the $68 billion Medicare beneficiaries in the U.S. covered by private insurers [11] - Concerns have been raised about the impact of privatization on patient care, as private insurers are known to deny medical coverage to maintain lower premiums [11]

Elevance Health (ELV) shares ended the last trading session 6.1% higher at $538.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.5% loss over the past four weeks. Elevance Health extended its rally for the second straight day, driven by continued optimism over its Health Benefits and Carelon businesses. Baird analyst Michael Ha also initiated coverage of the stock with an Outperform rating, which further drove ...

Shares of Elevance Health, Inc. (ELV) have jumped 14.9% in the year-to-date period compared with the 4.8% growth of the industry it belongs to, thanks to its strong operations, new contracts in its Government business and optimization efforts. Factors such as premium rate increases and inorganic growth initiatives are further enhancing its results, allowing the company to raise its guidance, which has been well-received by investors. Elevance Health, with a market capitalization of $127.3 billion, is one of ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What ar ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Investors might want to bet on Elevance Health (ELV) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors often ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

Key TakeawaysElevance Health exceeded earnings and revenue estimates for the first quarter and raised its outlook as it reported lower costs.The health insurer said it lowered its benefit expense ratio by 20 basis points and increased its total operating margin to 7.1%.Elevance shares were up nearly 4% in late trading Thursday, at their highest level since late 2022. Shares of Elevance Health (ELV) rose to their highest level since late 2022 on Thursday as the health insurance provider posted better-than-ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-16751 Securities registered pursuant to Section 12(b) of the Act: (Address of principal executive offices) (Zip Code) Registran ...